Production (Stage)
Cartesian Therapeutics, Inc.
RNAC
$10.32
-$0.10-0.96%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 34.17M | 38.91M | 47.94M | 54.10M | 25.91M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 34.17M | 38.91M | 47.94M | 54.10M | 25.91M |
| Cost of Revenue | 50.04M | 44.91M | 49.85M | 51.45M | 56.57M |
| Gross Profit | -15.87M | -5.99M | -1.91M | 2.65M | -30.67M |
| SG&A Expenses | 28.99M | 30.03M | 39.28M | 39.33M | 38.41M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 79.03M | 74.93M | 89.13M | 90.78M | 94.98M |
| Operating Income | -44.86M | -36.02M | -41.19M | -36.68M | -69.07M |
| Income Before Tax | -38.02M | -77.14M | -263.83M | -248.65M | -273.87M |
| Income Tax Expenses | 287.00K | 287.00K | -19.00M | -19.00M | -19.00M |
| Earnings from Continuing Operations | -38.31 | -77.42 | -244.83 | -229.65 | -254.87 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -38.31M | -77.42M | -244.83M | -229.65M | -254.87M |
| EBIT | -44.86M | -36.02M | -41.19M | -36.68M | -69.07M |
| EBITDA | -42.74M | -34.87M | -40.25M | -35.84M | -68.25M |
| EPS Basic | -1.64 | -11.45 | -51.70 | -52.31 | -55.12 |
| Normalized Basic EPS | -0.70 | -2.26 | -21.47 | -22.29 | -24.11 |
| EPS Diluted | -1.69 | -11.50 | -51.73 | -52.35 | -55.12 |
| Normalized Diluted EPS | -0.73 | -2.28 | -21.49 | -22.32 | -24.11 |
| Average Basic Shares Outstanding | 89.52M | 69.03M | 48.90M | 32.59M | 20.98M |
| Average Diluted Shares Outstanding | 90.59M | 70.10M | 49.97M | 33.66M | 20.98M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |